Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Oncology Reports|April 9, 2013
Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinomaKahori Seto, Junichi Shoda, Tomohisa Horibe, et al.
Biochimica Et Biophysica Acta|October 19, 2002
Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liverYasushi Matsuzaki, Bernard Bouscarel, Tadashi Ikegami, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2009
A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinomaNobuyoshi Fukumitsu, Shinji Sugahara, Hidetsugu Nakayama, et al.
International Journal of Environmental Research and Public Health|September 10, 2021
Relationships of Dietary Habits and Physical Activity Status with Non-Alcoholic Fatty Liver Disease Featuring Advanced FibrosisYoshito Yabe, Taeho Kim, Sechang Oh, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2019
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugateYoriko Yamashita-Kashima, Yasushi Yoshimura, Takaaki Fujimura, et al.
Journal of Gastroenterology|August 13, 2014
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumabToru Kawamoto, Kazunori Ishige, Melanie Thomas, et al.
Journal of Lipid Research|July 20, 2004
Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4Junichi Shoda, Yoichi Inada, Atsutoshi Tsuji, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 17, 2009
Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosisShinji Sugahara, Hidetsugu Nakayama, Kuniaki Fukuda, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2012
Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient miceKosuke Okada, Dongmei Ma, Eiji Warabi, et al.
Clinical & Experimental Metastasis|November 24, 2004
Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinomaHideo Suzuki, Junichi Shoda, Toru Kawamoto, et al.
Pageof 10